131 related articles for article (PubMed ID: 20862742)
21. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
22. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.
Schrohl AS; Christensen IJ; Pedersen AN; Jensen V; Mouridsen H; Murphy G; Foekens JA; Brunner N; Holten-Andersen MN
Mol Cell Proteomics; 2003 Mar; 2(3):164-72. PubMed ID: 12672830
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y
Cancer Lett; 2000 Apr; 151(1):81-6. PubMed ID: 10766426
[TBL] [Abstract][Full Text] [Related]
24. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.
Jung K; Nowak L; Lein M; Priem F; Schnorr D; Loening SA
Int J Cancer; 1997 Apr; 74(2):220-3. PubMed ID: 9133459
[TBL] [Abstract][Full Text] [Related]
26. Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer.
Laitinen A; Hagström J; Mustonen H; Kokkola A; Tervahartiala T; Sorsa T; Böckelman C; Haglund C
Tumour Biol; 2018 Sep; 40(9):1010428318799266. PubMed ID: 30192205
[TBL] [Abstract][Full Text] [Related]
27. High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma.
Kuvaja P; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Int J Cancer; 2008 Aug; 123(4):846-51. PubMed ID: 18506691
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y
Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408
[TBL] [Abstract][Full Text] [Related]
29. High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the serum are associated with poor prognosis in HPV-negative squamous cell oropharyngeal cancer.
Carpén T; Sorsa T; Jouhi L; Tervahartiala T; Haglund C; Syrjänen S; Tarkkanen J; Mohamed H; Mäkitie A; Hagström J; Mattila PS
Cancer Immunol Immunother; 2019 Aug; 68(8):1263-1272. PubMed ID: 31240326
[TBL] [Abstract][Full Text] [Related]
30. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
31. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Ho D; Huang J; Chapman JW; Leitzel K; Ali SM; Shepherd L; Parulekar WR; Ellis CE; Crescnzo RJ; Zhu L; Virk S; Nomikos D; Aparicio S; Gelmon KA; Carney WP; Lipton A
Breast Cancer Res Treat; 2017 Aug; 164(3):571-580. PubMed ID: 28484925
[TBL] [Abstract][Full Text] [Related]
32. Serum TIMP-1 predicts survival outcomes of invasive breast carcinoma patients: a meta-analysis.
Lee JH; Choi JW; Kim YS
Arch Med Res; 2011 Aug; 42(6):463-8. PubMed ID: 21945575
[TBL] [Abstract][Full Text] [Related]
33. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
34. Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal cancer patients: associations with clinicopathological variables and patient survival.
Giaginis C; Nikiteas N; Margeli A; Tzanakis N; Rallis G; Kouraklis G; Theocharis S
Int J Biol Markers; 2009; 24(4):245-52. PubMed ID: 20108216
[TBL] [Abstract][Full Text] [Related]
35. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer.
Yamada Y; Sakamoto S; Rii J; Yamamoto S; Kamada S; Imamura Y; Nakamura K; Komiya A; Nakatsu H; Ichikawa T
Prostate; 2020 May; 80(7):559-569. PubMed ID: 32134137
[TBL] [Abstract][Full Text] [Related]
37. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction.
Cavusoglu E; Ruwende C; Chopra V; Yanamadala S; Eng C; Clark LT; Pinsky DJ; Marmur JD
Am Heart J; 2006 May; 151(5):1101.e1-8. PubMed ID: 16644343
[TBL] [Abstract][Full Text] [Related]
38. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
[TBL] [Abstract][Full Text] [Related]
40. [The subgroup analysis of the prognostic value of the intraductal carcinoma of the prostate in patients with metastatic prostate cancer].
Zhao JG; Nie L; Chen XQ; Chen N; Zeng H
Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):422-427. PubMed ID: 31142066
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
